Kolon Life Science Inc. (KOSDAQ: 102940)

Market Cap	282.01B
Revenue (ttm)	147.98B
Net Income (ttm)	-89.77B
Shares Out	12.42M
EPS (ttm)	-7,681.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,350
Open	23,150
Previous Close	23,150
Day's Range	22,300 - 23,150
52-Week Range	16,780 - 31,000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 13, 2025

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2000
• Employees: 420
• Stock Exchange: KOSDAQ
• Ticker Symbol: 102940